Brf113928 nct01336634
WebMay 20, 2013 · The BRAF inhibitor dabrafenib has demonstrated clinical activity in BRAF V600 mutation–positive melanoma. Here we report interim efficacy and safety data …
Brf113928 nct01336634
Did you know?
WebThis is the first NGS oncology panel test approved by the FDA for multiple companion diagnostic indications. The approvals are based on Study BRF113928 (NCT01336634), … WebMay 9, 2024 · Evaluation of dabrafenib in patients with BRAF‐mutant NSCLC is also under way in an open‐label, multicohort phase II trial (BRF113928; NCT01336634). Cohort A of this trial was designated for evaluation of the clinical activity of dabrafenib monotherapy, primarily in patients with previously treated BRAF V600E‐mutant NSCLC [ 22 ].
WebRPC34 34-kDa subunit of RNA polymerase III (C) [] Gene ID: 4838428, updated on 24-Apr-2024. Summary WebThe overall RR was 67% in the dabrafenib/trametinib group and 51% in the dabrafenib-only group ( p =0.002). The 6-month OS was 93% with dabrafenib/trametinib and 85% with dabrafenib alone ( p =0.02) ( Table 1 ). 34 These collective results demonstrated the utility of BRAF/MEK inhibition combination therapy in melanoma.
WebBRF113928 (NCT01336634) was the pivotal study supporting the regular approval of dabrafenib and trametinib combination, for metastatic nonsmall cell lung cancer (NSCLC) with BRAF V600E mutation in 2024, which is … Webcontrolled study (BRF113928; NCT01336634). Hence, to link dabrafenib ? trametinib into the evidence network, an externally controlled comparison was conducted between the dabrafenib ? trametinib trial and the nivolu-mab trial (Checkmate 057; NCT01673867) using a matching-adjusted indirect comparison (MAIC) approach. The nivolumab arm from
WebGene ID: 18913428, updated on 19-Sep-2024. Summary. Other designations. hypothetical protein
WebMay 20, 2024 · Initial cohorts of the BRF113928 (NCT01336634) trial evaluated efficacy and safety of D monotherapy (cohort A; n = 78) or D + T (cohort B; n = 57) in pts with previously treated BRAFV600E–mutant... eagle school district jobsWebJun 23, 2024 · The approvals are based on Study BRF113928 (NCT01336634), an international, multicenter, three-cohort, non-randomized, non-comparative, open-label, trial in patients with locally confirmed BRAF V600E mutation-positive metastatic NSCLC. Ninety-three patients were treated with the combination of dabrafenib (150 mg orally twice daily) … eagle scholarship applicationWebMay 20, 2013 · This study represents the first clinical evidence of BRAF as a therapeutic target in NSCLC. Clinical trial information: NCT01336634. No full-text available Request … csl vancouver waWebDabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patients with advanced non-small-cell lung cancer (NSCLC) … eagle school auto parts martinsburgWebThe FDA primarily relied on data from the study BRF113928 (NCT01336634), an international, multicohort, nonrandomized, open-label,activity … eagle scholarship portal loginWebOct 1, 2024 · Pooled analysis of data from the following trials: NCT01227889, NCT01153763, NCT01266967, NCT01072175, NCT00880321, NCT01336634, NCT01584648, NCT01597908, NCT01682083, NCT01245062, NCT01037127, NCT00687622. Editorial acknowledgement Allison Lytle, PhD, from ArticulateScience … eagles choking memeWebJun 7, 2016 · The multi-cohort study, which the developer of the combination Novartis called pivotal, continues to enroll participants (NCT01336634). A third cohort is assessing the combination as a frontline therapy for patients with BRAF -mutated NSCLC. This portion of the study has fully accrued 34 patients, with results expected in the near future. eagle school intermediate lunch menu